Evidence map›Paper›PMID 42200795›Full record

ReviewNano letters2026

Gold Nanoparticles in Central Nervous System Diseases: Recent Progress, Challenges, and Therapeutic Opportunities.

Shunping Han, Salima Bouchrara, Khuloud T Al-Jamal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nano letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shunping HanInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.
Salima BouchraraInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.ORCID 0009-0003-1317-6144
Khuloud T Al-JamalInstitute of Pharmaceutical Science, Faculty of Life Sciences & Medicine, King's College London, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom.ORCID 0000-0001-5165-2699

Funding

Wellcome Trust WT103913
6 · The paper itself

Abstract

Central nervous system (CNS) diseases, including neurodegenerative disorders and brain cancers, remain leading causes of disability and death, largely due to limited drug penetration across the blood-brain barrier (BBB). Gold nanoparticles (AuNPs) have emerged as versatile platforms for CNS applications, with tunable morphology, surface chemistry, and optical properties, enabling both therapeutic and diagnostic use. This review highlights recent advances in the design and optimization of AuNPs for brain-targeted delivery, explores their applications in CNS diseases, and discusses current challenges, safety considerations, and future prospects for clinical translation.

Indexed as

Central Nervous System DiseasesGoldMetal NanoparticlesAnimalsBlood-Brain BarrierDrug Delivery SystemsHumansGoldBrain deliveryCentral nervous system diseasesGold nanoparticlesTherapeutic applicationToxicity

Identifiers

PMID42200795
PMCPMC13267172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.